{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"PFS is defined as the interval between the first dose of study medication and the earliest date of disease progression or death due to any cause. This analysis was planned but not performed for Part 2 as the study was terminated early during Part 1.","groups":[{"description":"Participants with GCB-DLBCL-mutant and wild type, TFL-mutant and wild type as well as participants with MM were planned to be enrolled in Part 2 of the study. Participants enrolled in Part 2 were planned to receive RP2D .","id":"OG000","title":"Part 2: All Participants"}],"populationDescription":"All Subjects Population. Data was not collected in Part 2 as no participant was enrolled in Part 2.","reportingStatus":"POSTED","timeFrame":"Up to 3.2 years","title":"Part 2: Number of Participants With Progression Free Survival","type":"SECONDARY"}